The aim of this study is evaluate to the cellular viability of elution from the newly developed resin and Osteobond® in vitro. The basis of the newly developed resin are methacryloyloxyethyl methyl succinate and 1,6-Hexanediol dimethacrylate. The basis of Osteobond is methyl methacrylate. The concentrations of basis in each elution were determined by high-performance liquid chromatography (HPLC). Cellular viabilities of L-929 mouse fibroblasts were evaluated by direct cells counting, and then, each IC50 value was calculated. Moreover, patterns of cell death were analyzed using annexin V/propidium iodide staining with the phase-contrast microscope and flow cytometry. The concentration of Osteobond elution was 2.16 mM of MMA, and the newly developed resin elution was 1.02 mM of TA and 1.87 x 10-2 mM of HX. Until 72 hours of incubation, treatment with each elution impaired the viability of L-929 cells in a dose-dependent manner. IC50 value of Osteobond was 6.48 x 10-4 mM of MMA. However, IC50 of the newly developed resin was not calculated. Treatment with Osteobond elution showed more necrotic cells than with the newly developed resin elution. In conclusion, the results demonstrated much more excellent cellular viability of the newly developed resin than that of MMA resin. Thus, it is suggested that the newly developed resin will be more useful as an implantation material for dentistry and orthopaedics.